IHS Chemical Week

Regions :: North America

Aurobindo receives FDA approval for generic Cymbalta

5:23 AM MST | December 13, 2013 | Natasha Alperowicz

Aurobindo Pharma (Hyderabad) said today that it has received final approval from the FDA to manufacture and market duloxetine hydrochloride delayed-release capsules 20, 30 and 60 mg. The product is the generic equivalent of Eli Lilly’s Cymbalta drug, used to treat major depressive disorders. The market size in the US for this product last year was estimated by IMS to be in the region of $5.4-5.5 billion.   Aurobindo is the third Indian company to announce FDA’s approval for the product. On Thursday Sun Pharmaceutical Industries (Mumbai) and Lupin...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa